Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.06 | 0.01 | -0.05 |
| FCF Yield | 16.34% | -9.82% | -12.35% | 30.19% |
| EV / EBITDA | -15.71 | -25.49 | 7.48 | 16.25 |
| Quality | ||||
| ROIC | -7.33% | -4.83% | 12.81% | 3.92% |
| Gross Margin | 83.59% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -3.71 | 2.82 | -0.97 | 9.59 |
| Growth | ||||
| Revenue 3-Year CAGR | 5,662,151.85% | 5,624,978.85% | 5,422,926.95% | 4,228,689.36% |
| Free Cash Flow Growth | 374.00% | 22.65% | -136.57% | 701.78% |
| Safety | ||||
| Net Debt / EBITDA | 5.97 | 2.11 | -0.80 | -12.05 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -588.30 | 9.20 | 1.49 | 0.26 |